Arpadi S M, Markowitz L E, Baughman A L, Shah K, Adam H, Wiznia A, Lambert G, Dobroszycki J, Heath J L, Bellini W J
Bronx-Lebanon Hospital Center, USA.
Pediatrics. 1996 May;97(5):653-7.
The goals of this study were to evaluate the proportion of previously vaccinated human immunodeficiency virus (HIV) type 1-infected children with detectable postvaccination measles antibody; to assess risk factors for vaccine failure; and to evaluate the response to reimmunization.
A total of 81 perinatally HIV-infected children receiving medical care in the Bronx, New York who had previously received measles vaccine were enrolled. The Centers for Disease Control and Prevention (CDC) HIV class, lymphocyte subsets, and measles antibody were determined upon enrollment. Additional data abstracted from medical records included dates and number of prior measles vaccinations and CDC HIV class at the time of vaccination. Measles antibody was determined by microneutralization enzyme-linked immunosorbent assay (ELISA).
The median age at time of study was 42 months (range, 9 to 168 months). Overall, 58 (72%) subjects had detectable measles antibody (microneutralization ELISA titer > 1:5). Children studied within 1 year of vaccination were more likely to have detectable measles antibody than children evaluated more than 1 year after vaccination (83% vs 52%, P < .01). The proportion of children with detectable measles antibody was higher among children with no or moderate immunosuppression compared to those with severe immunosuppression when immune status was based on CD4%. Children vaccinated at 6 to 11 months of age appeared to have a higher proportion of detectable measles antibody than those who received a first measles vaccination after age 1. Only 1 (14%) of 7 previously vaccinated children who were seronegative or had very low titers experienced a four-fold rise in measles antibody when reimmunized.
These results support current recommendations to vaccinate HIV-infected children against measles. The proportion of children with detectable measles antibody among vaccinated HIV-infected children is considerably lower than in vaccinated healthy children. HIV-infected children may respond better to measles vaccine when it is administered before the first birthday. From our limited data it appears that reimmunization of previously vaccinated HIV-infected children with moderate to severe immunosuppression does not result in an antibody recall response.
本研究的目的是评估先前接种过疫苗的1型人类免疫缺陷病毒(HIV)感染儿童接种疫苗后可检测到麻疹抗体的比例;评估疫苗接种失败的危险因素;并评估再次免疫的反应。
共有81名在纽约布朗克斯接受医疗护理的围产期HIV感染儿童入组,这些儿童之前已接种过麻疹疫苗。入组时测定疾病控制和预防中心(CDC)HIV分类、淋巴细胞亚群和麻疹抗体。从医疗记录中提取的其他数据包括先前麻疹疫苗接种的日期和次数以及接种时的CDC HIV分类。麻疹抗体通过微量中和酶联免疫吸附测定(ELISA)确定。
研究时的中位年龄为42个月(范围9至168个月)。总体而言,58名(72%)受试者可检测到麻疹抗体(微量中和ELISA滴度>1:5)。与接种疫苗1年以后接受评估的儿童相比,在接种疫苗1年内接受研究的儿童更有可能检测到麻疹抗体(83%对52%,P<.01)。当根据CD4%确定免疫状态时,与重度免疫抑制儿童相比,无或中度免疫抑制儿童中可检测到麻疹抗体的儿童比例更高。6至11个月龄接种疫苗的儿童中可检测到麻疹抗体者的比例似乎高于1岁以后首次接种麻疹疫苗的儿童。7名先前接种过疫苗但血清学阴性或滴度极低的儿童中,只有1名(14%)再次免疫后麻疹抗体呈四倍升高。
这些结果支持目前关于HIV感染儿童接种麻疹疫苗的建议。接种疫苗的HIV感染儿童中可检测到麻疹抗体的儿童比例远低于接种疫苗的健康儿童。HIV感染儿童在1周岁前接种麻疹疫苗可能反应更好。根据我们有限的数据,先前接种过疫苗且有中度至重度免疫抑制的HIV感染儿童再次免疫似乎不会引发抗体回忆反应。